BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Premium Article

The 10 Deals That Defined APAC Biopharma in 2026

The biggest pharma deals of 2026 with an Asia-Pacific principal are easy to list and hard to rank. The ten on this page carry more than US$70 billion in he...

September 24, 2026 | Analysis

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

6 Radiopharmaceutical Programmes and Sites to Watch in APAC

Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...

August 18, 2026 | Analysis

Why Asia Pacific Must Rethink Chronic Care Before the Demographic Tipping Point

Asia Pacific’s ageing economies are entering a more demanding phase of healthcare planning. As populations live longer, the challenge for healthcare ...

August 10, 2026 | Opinion | By Ambra Debernardi, Head of Employee Benefits and Corporate Relationships, APAC, Zurich Insurance

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

July 06, 2026 | Analysis

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 30, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

Stay Connected